Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
- Author
- SCHULTHEIS, Anne M1 ; LURJE, Georg1 ; HIRTE, Hal4 ; FLEMING, Gini5 ; ROMAN, Lynda1 ; LENZ, Heinz-Josef1 ; RHODES, Katrin E1 ; WU ZHANG1 ; DONGYUN YANG1 ; GARCIA, Agustin A1 ; MORGAN, Robert2 ; GANDARA, David3 ; SCUDDER, Sidney3 ; OZA, Amit4
[1] University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, United States
[2] City of Hope National Medical Center, Duarte, California, United States
[3] University of California, Davis Cancer Center, Sacramento, California, United States
[4] Princess Margaret Hospital, Toronto, Ontario, Canada
[5] University of Chicago, Chicago, Illinois, United States - Source
Clinical cancer research (Print). 2008, Vol 14, Num 22, pp 7554-7563, 10 p ; ref : 41 ref
- CODEN
- CCREF4
- ISSN
- 1078-0432
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antiangiogénique Anticancéreux Bévacizumab Cancer de l'ovaire Cyclophosphamide Facteur croissance endothélium vasculaire Génotype Polymorphisme Pronostic Récidive Traitement Variabilité génétique Anti-VEGF Agent alkylant Anticorps monoclonal Cancer Dérivé de l'oxazaphosphinane Moutarde à l'azote Pathologie de l'appareil génital femelle Pathologie des ovaires Tumeur maligne
- Keyword (en)
- Antiangiogenic agent Antineoplastic agent Bevacizumab Ovary cancer Cyclophosphamide Vascular endothelium growth factor Genotype Polymorphism Prognosis Relapse Treatment Genetic variability Alkylating agent Monoclonal antibody Cancer Oxazaphosphinane derivatives Nitrogen mustard Female genital diseases Ovarian diseases Malignant tumor
- Keyword (es)
- Antiangiogenico Anticanceroso Bevacizumab Cáncer del ovario Ciclofosfamida Factor crecimiento endotelio vascular Genotipo Polimorfismo Pronóstico Recaida Tratamiento Variabilidad genética Agente alquilante Anticuerpo monoclonal Cáncer Oxazafosfinano derivado Mostaza al nitrógeno Aparato genital hembra patología Ovario patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20C Female genital diseases / 002B20C02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20971391
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/1078-0432.CCR-08-0351 
https://dx.doi.org/10.1158/1078-0432.CCR-08-0351
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-08-0351\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:108:\"Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:2:\"22\";s:8:\"\u0000*\u0000spage\";s:4:\"7554\";s:8:\"\u0000*\u0000epage\";s:4:\"7563\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SCHULTHEIS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Anne M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:12:\"LURJE, Georg\";i:1;s:10:\"HIRTE, Hal\";i:2;s:13:\"FLEMING, Gini\";i:3;s:12:\"ROMAN, Lynda\";i:4;s:17:\"LENZ, Heinz-Josef\";i:5;s:16:\"RHODES, Katrin E\";i:6;s:8:\"WU ZHANG\";i:7;s:12:\"DONGYUN YANG\";i:8;s:17:\"GARCIA, Agustin A\";i:9;s:14:\"MORGAN, Robert\";i:10;s:14:\"GANDARA, David\";i:11;s:15:\"SCUDDER, Sidney\";i:12;s:9:\"OZA, Amit\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:108:\"Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-08-0351\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:108:\"Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:2:\"22\";s:8:\"\u0000*\u0000spage\";s:4:\"7554\";s:8:\"\u0000*\u0000epage\";s:4:\"7563\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SCHULTHEIS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Anne M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:12:\"LURJE, Georg\";i:1;s:10:\"HIRTE, Hal\";i:2;s:13:\"FLEMING, Gini\";i:3;s:12:\"ROMAN, Lynda\";i:4;s:17:\"LENZ, Heinz-Josef\";i:5;s:16:\"RHODES, Katrin E\";i:6;s:8:\"WU ZHANG\";i:7;s:12:\"DONGYUN YANG\";i:8;s:17:\"GARCIA, Agustin A\";i:9;s:14:\"MORGAN, Robert\";i:10;s:14:\"GANDARA, David\";i:11;s:15:\"SCUDDER, Sidney\";i:12;s:9:\"OZA, Amit\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:108:\"Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-08-0351\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-08-0351\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:108:\"Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:2:\"22\";s:8:\"\u0000*\u0000spage\";s:4:\"7554\";s:8:\"\u0000*\u0000epage\";s:4:\"7563\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SCHULTHEIS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Anne M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:12:\"LURJE, Georg\";i:1;s:10:\"HIRTE, Hal\";i:2;s:13:\"FLEMING, Gini\";i:3;s:12:\"ROMAN, Lynda\";i:4;s:17:\"LENZ, Heinz-Josef\";i:5;s:16:\"RHODES, Katrin E\";i:6;s:8:\"WU ZHANG\";i:7;s:12:\"DONGYUN YANG\";i:8;s:17:\"GARCIA, Agustin A\";i:9;s:14:\"MORGAN, Robert\";i:10;s:14:\"GANDARA, David\";i:11;s:15:\"SCUDDER, Sidney\";i:12;s:9:\"OZA, Amit\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:108:\"Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-08-0351\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:108:\"Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:2:\"22\";s:8:\"\u0000*\u0000spage\";s:4:\"7554\";s:8:\"\u0000*\u0000epage\";s:4:\"7563\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SCHULTHEIS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Anne M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:12:\"LURJE, Georg\";i:1;s:10:\"HIRTE, Hal\";i:2;s:13:\"FLEMING, Gini\";i:3;s:12:\"ROMAN, Lynda\";i:4;s:17:\"LENZ, Heinz-Josef\";i:5;s:16:\"RHODES, Katrin E\";i:6;s:8:\"WU ZHANG\";i:7;s:12:\"DONGYUN YANG\";i:8;s:17:\"GARCIA, Agustin A\";i:9;s:14:\"MORGAN, Robert\";i:10;s:14:\"GANDARA, David\";i:11;s:15:\"SCUDDER, Sidney\";i:12;s:9:\"OZA, Amit\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:108:\"Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-08-0351\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:108:\"Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:2:\"22\";s:8:\"\u0000*\u0000spage\";s:4:\"7554\";s:8:\"\u0000*\u0000epage\";s:4:\"7563\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SCHULTHEIS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Anne M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:12:\"LURJE, Georg\";i:1;s:10:\"HIRTE, Hal\";i:2;s:13:\"FLEMING, Gini\";i:3;s:12:\"ROMAN, Lynda\";i:4;s:17:\"LENZ, Heinz-Josef\";i:5;s:16:\"RHODES, Katrin E\";i:6;s:8:\"WU ZHANG\";i:7;s:12:\"DONGYUN YANG\";i:8;s:17:\"GARCIA, Agustin A\";i:9;s:14:\"MORGAN, Robert\";i:10;s:14:\"GANDARA, David\";i:11;s:15:\"SCUDDER, Sidney\";i:12;s:9:\"OZA, Amit\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:108:\"Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
